| Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. | |
| | |
MedLine Citation:
|
PMID: 20635928 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cancer stem-like cells (CSCs)/tumor-initiating cells (TICs) are a small population of cancer cells that have the properties of tumor-initiating ability, self-renewal and differentiation. These properties suggest that CSCs/TICs are essential for tumor maintenance, recurrence and distant metastasis. Thus, elimination of CSCs/TICs is essential to cure malignant diseases. However, there are several studies reporting that CSCs/TICs are more resistant to standard cancer therapies, including chemotherapy and radiotherapy, than non-CSC/TIC populations. How then, can we eliminate CSCs/TICs? Immunotherapy might be the possible answer. In recent analysis, innate immunity (natural killer cells and gammadeltaT cells) and also adaptive immunity (cytotoxic T lymphocyte-based cellular immunity and antibody-based humoral immunity) can recognize CSCs/TICs in vitro efficiently. Furthermore, CSC/TIC-specific monoclonal antibody therapies are also efficient in vivo. In this article, we describe the potency, possibilities and problems of CSC/TIC-targeting immunotherapy. |
| | |
Authors:
|
Yoshihiko Hirohashi; Toshihiko Torigoe; Satoko Inoda; Akari Takahashi; Rena Morita; Satoshi Nishizawa; Yasuaki Tamura; Hiromu Suzuki; Minoru Toyota; Noriyuki Sato |
Related Documents
:
|
48258 - Selective immunosuppressive activity of steroids in mice inoculated with the moloney sa... 17885078 - Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived sup... 19159828 - Human embryo immune escape mechanisms rediscovered by the tumor. 752118 - Delayed hypersensitivity reactions in patients with breast cancer. 12134908 - Invasion of human glioma biopsy specimens in cultures of rodent brain slices: a quantit... 10458408 - Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitr... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Immunotherapy Volume: 2 ISSN: 1750-7448 ISO Abbreviation: Immunotherapy Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-11-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101485158 Medline TA: Immunotherapy Country: England |
Other Details:
|
Languages: eng Pagination: 201-11 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adaptive Immunity Aldehyde Dehydrogenase / analysis Antibodies, Neoplasm / immunology Antigens, Neoplasm / immunology* Antigens, Surface / immunology Feasibility Studies Forecasting Humans Immunity, Innate Immunotherapy / methods* Isoenzymes / analysis Killer Cells, Natural / immunology Models, Biological Neoplasms / immunology, therapy Neoplastic Stem Cells / chemistry, immunology* T-Lymphocyte Subsets / immunology T-Lymphocytes, Cytotoxic / immunology Tumor Markers, Biological / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Neoplasm; 0/Antigens, Neoplasm; 0/Antigens, Surface; 0/Isoenzymes; 0/Tumor Markers, Biological; EC 1.2.1.-/aldehyde dehydrogenase 1; EC 1.2.1.3/Aldehyde Dehydrogenase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New perspectives in cancer virotherapy: bringing the immune system into play.
Next Document: HER-2/neu as a target for cancer vaccines.